恶性淋巴瘤患者细胞活化因子的表达及对疾病进展的影响

Expression of Cell Activation Factor in Patients with Malignant Lymphoma and its Effect on Disease Progression

目的:探讨恶性淋巴瘤患者细胞活化因子的表达与对疾病进展和继发静脉血栓栓塞的影响。方法:选择2016年1月至2018年12月我院收治的30例恶性淋巴瘤患者为研究组,同期健康体检者30例为对照组,比较分析研究组治疗前后及对照组血清可溶性血栓调节蛋白(sTM)、全血中性粒细胞的表面CD11b因子以及血小板表面CD62p因子表达水平。结果:研究组治疗前sTM、CD11b、CD62p各因子水平明显高于研究组治疗后及对照组(P<0.05),治疗后各因子水平较治疗前明显降低,差异有统计学意义(P<0.05),但治疗后与对照组比较各因子水平差异无统计学意义(P>0.05)。结论:内皮细胞损伤、中性粒细胞及血小板表面因子异常活化易导致恶性淋巴瘤患者易栓、疾病进展和继发静脉血栓栓塞,临床早期发现,及时治疗有助于改善预后。

Objective: To investigate the effect of cell activation factor expression on disease progression and secondary venous thromboembolism in patients with malignant lymphoma.Methods: Between January 2016 and December 2018, 30 cases of malignant lymphoma patients as research group in our hospital, in the same period health check-up 30 cases as control group, the comparative analysis research group and the control group before and after the treatment serum soluble thrombus regulatory proteins(sTM), the surface of the whole blood neutrophils CD11 b factor and platelet CD62 p factor on the surface level.Results: The levels of sTM, CD11 b and CD62 p in the study group before treatment were significantly higher than those in the study group and control group(P<0.05), and the levels of each factor were significantly lower after treatment than before treatment, with statistically significant differences in the group(P<0.05), but no statistically significant differences in the levels of each factor after treatment compared with the control group(P>0.05).Conclusion: Endothelial cell injury, abnormal activation of neutrophils and platelet surface factors are likely to lead to thromboembolism, disease progression and secondary venous thromboembolism in patients with malignant lymphoma.